Determinants of Drug-Coated Balloon Failure in Patients Undergoing Femoropopliteal Arterial Intervention

Krishnan, Prakash; Farhan, Serdar; Schneider, Peter A.; Kamran, Haroon; Iida, Osamu; Brodmann, Marianne; Micari, Antonio; Sachar, Ravish; Urasawa, Kasuki; Scheinert, Dierk; Ando, Kenji; Tarricone, Arthur; Doros, Gheorghe; Tepe, Gunnar; Yokoi, Hiroyoshi; Laird, John; Zeller, Thomas

doi:10.1016/j.jacc.2022.06.043

Cited by 12 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although limited real-world clinical findings were available during the DCB's launch, Fanelli et al reported that calcification greater than 270° was a predictor of recurrence 9) . Subsequently, long lesions, smaller MLA, and larger residual stenosis were also reported as predictors of recurrence 6,8,17) . Fujihara et al reported that the severity of angiographic dissection was correlated with the recurrence rate after POBA 16) .…”

Section: Freedom From Cd-tlr At 12 Monthsmentioning

confidence: 94%

Validation of the Usefulness of the Diameter Reduction, Spiral Shape, Flow Impairment, or Adverse Morphology Classification System in Real-World Clinical Practice

Yamada

Tokuda

Yoshioka

et al. 2024

JAT

View full text Add to dashboard Cite

Aim:The accuracy of the DISFORM (diameter reduction, spiral shape, flow impairment, or adverse morphology) classification system has not been validated. Methods: This retrospective multicenter observational study enrolled 288 consecutive patients with lower extremity artery disease who underwent endovascular therapy with drug-coated balloons for femoropopliteal lesions between January 2018 and December 2021. Patients were classified into DISFORM I-IV groups. Primary patency (PP) and freedom from clinically driven target lesion revascularization (CD-TLR) at 12 months, and recurrence predictors at 12 months were investigated.Results: In total, 183, 66, 11, and 28 patients were classified into DISFORM I, II, III, and IV groups, respectively. In the DISFORM I, II, III, and IV groups, the PP rates were 75.3%, 91.1%, 87.5%, and 50.0%, respectively, and freedom from CD-TLR rates were 86.0%, 91.6%, 88.9%, and 76.7%, respectively, at 12 months. In the DISFORM I-III and IV groups, the PP rates were 79.4% and 50.0%, respectively, and freedom from CD-TLR rates were 87.5% and 76.7%, respectively, at 12 months. Multivariate analysis showed that chronic limb-threatening ischemia, DISFORM IV, and Lutonix™ use were independent predictors of PP loss at 12 months. Conclusion:DISFORM IV had a lower PP rate than DISFORM I-III in midterm phase.

show abstract

Section: Freedom From Cd-tlr At 12 Monthsmentioning

confidence: 94%

Validation of the Usefulness of the Diameter Reduction, Spiral Shape, Flow Impairment, or Adverse Morphology Classification System in Real-World Clinical Practice

Yamada

Tokuda

Yoshioka

et al. 2024

JAT

View full text Add to dashboard Cite

show abstract

“…21 Nonetheless, EVT is ineffective and, in some cases, inappropriate for some SFA lesions. For example, worse clinical outcomes following EVT have been reported for lesions with severe calcification, 22-24 those with a small diameter, 22, 25 and long (>25 cm) lesions. 26 In these cases, BS should still be provided, especially when multiple risk factors for EVT are present 22 or the patient is young and needs long-term results.…”

Section: Data Availabilitymentioning

confidence: 99%

Long-Term Outcomes of a Japanese Prospective Multicenter Registry Using a Heparin-Bonded Expanded Polytetrafluoroethylene Graft for Above-the-Knee Femoropopliteal Bypasses

Fujimura,

Obara,

Matsubara

et al. 2024

Circ J

View full text Add to dashboard Cite

conferred good clinical results. 6,7 These results, together with the high morbidity and longer hospital stay associated with bypass surgery (BS), 8 supported the recommendations in guidelines for EVT of the SFA lesion; 4,5 the 2017 European Society of Cardiology guidelines recommended EVT for SFA lesions with a length of up to 25 cm. 3 For BS, all guidelines recommend the use of a good W ith recent advances in endovascular technologies and techniques, endovascular treatment (EVT) for the revascularization of lower extremity arterial disease (LEAD) has been increasingly used. 1-5 Even in complex superficial femoral artery (SFA) lesions, EVT, especially with the Viabahn stent graft (W.L. Gore & Associates, Flagstaff, AZ, USA) for long lesions, has

show abstract

Multicenter, retrospective registry of isolated atherosclerotic popliteal arteries treated with endovascular revascularization

Horie

Takahara

Nakama³

et al. 2023

Heart Vessels

View full text Add to dashboard Cite

Determinants of Drug-Coated Balloon Failure in Patients Undergoing Femoropopliteal Arterial Intervention

Cited by 12 publications

References 29 publications

Validation of the Usefulness of the Diameter Reduction, Spiral Shape, Flow Impairment, or Adverse Morphology Classification System in Real-World Clinical Practice

Validation of the Usefulness of the Diameter Reduction, Spiral Shape, Flow Impairment, or Adverse Morphology Classification System in Real-World Clinical Practice

Long-Term Outcomes of a Japanese Prospective Multicenter Registry Using a Heparin-Bonded Expanded Polytetrafluoroethylene Graft for Above-the-Knee Femoropopliteal Bypasses

Multicenter, retrospective registry of isolated atherosclerotic popliteal arteries treated with endovascular revascularization

Contact Info

Product

Resources

About